전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,373 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Toripalimab)

Muscle Invasive Bladder Cancer; HER2 Expression · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#MuscleInvasiveBladderCancer+2
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab vedotin + Sintilimab + Multimodality radiotherapy)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveAdvancedGastricCanc+1
Trials 1Status Recruiting
ADCLimited DatastaleThe First Affiliated Hospital w…Phase 2

Disitamb Vedotin ,pyrotinib (Disitamb Vedotin ,pyrotinib)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#antibody-drug-conjugate#The
Trials 1Status Recruiting
AntibodyLimited DatastaleMerrimack PharmaceuticalsPhase 1

trastuzumab (Herceptin, Docetaxel, trastuzumab and MM-111)

HER-2 Gene Amplification · HER-2 Gene Amplification

#HER-2GeneAmplification#Antibody#Phase1#monoclonal-antibody#Merrimack
Trials 1Status Active
AntibodyLimited DatastaleGilead SciencesPhase 2

DOM (Domvanalimab, Domvanalimab (DOM))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#monoclonal-antibody#AdvancedorMetastaticNon-Small-Ce+1
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy (Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy)

B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleTesaro, Inc.Phase 3

TSR-042 (Dostarlimab, Dostarlimab (TSR-042))

Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma · Ovarian Neoplasms

#OvarianNeoplasms#Antibody#Phase3#monoclonal-antibody#Ovarian+2
Trials 1Status Recruiting
AntibodyLimited DatastaleAbbViePhase 3

adalimumab (Humira, Double-blind adalimumab)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#monoclonal-antibody#AbbVie
Trials 1Status Active
AntibodyLimited DatastaleQilu Hospital of Shandong Unive…Preclinical

Doublet or triplet chemotherapy combined with cetuximab (Doublet or triplet chemotherapy combined with cetuximab)

Colon Cancer · Colon Cancer

#ColonCancer#Antibody#Preclinical#monoclonal-antibody#Qilu
Trials 1Status Active
AntibodyLimited DatastaleAbbViePreclinical

adalimumab (Humira, Dovobet, neotigason, etanercept, adalimumab. infliximab)

Psoriasis · Psoriasis

#Psoriasis#Antibody#Preclinical#monoclonal-antibody#AbbVie
Trials 1Status Active
AntibodyLimited DatastaleJanssenPreclinical

daratumumab (Darzalex, Dratumumab / Hyaluronidase Injection [Darzalex Faspro])

Light Chain (AL) Amyloidosis · Light Chain (AL) Amyloidosis

#LightChainALAmyloidosis#Antibody#Preclinical#monoclonal-antibody#Janssen
Trials 1Status Recruiting
AntibodyLimited DatastaleSichuan Kelun-Biotech Biopharma…Phase 1

Drug: Tagitanlimab Drug: Capecitabine (Drug: Tagitanlimab Drug: Capecitabine)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase1#monoclonal-antibody#Sichuan
Trials 1Status Recruiting
CGTLimited DatastaleBeijing Boren HospitalPhase 1

Dual CD33/CLL1 CAR T (Dual CD33/CLL1 CAR T)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Dual Specificity CD38 and bcma CAR-T Cells (Dual Specificity CD38 and bcma CAR-T Cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleEssen BiotechPhase 2

Dual-Target Antigen-Selected CAR-NK (Dual-Target Antigen-Selected CAR-NK)

Cancer; Breast Cancer · MET

#MET#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DT-CAR-NK (Dual-target CAR-NK cells, Dual-target CAR-NK cells (EB-DT-CAR-NK))

Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Dual-targeting BCMA-CD19 CAR-T cell infusion (Dual-targeting BCMA-CD19 CAR-T cell infusion)

Relapsed or Refractory Multiple Myeloma (RRMM) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting CLDN18.2 and PD-L1 CAR-T cells (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Advanced Solid Tumor · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting HER2 and PD-L1 CAR-T cells (Dual-targeting HER2 and PD-L1 CAR-T cells)

Peritoneal Carcinoma Metastatic; Pleural Effusion, Malignant · HER2

#HER2#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting VEGFR1 and PD-L1 CAR-T cells (Dual-targeting VEGFR1 and PD-L1 CAR-T cells)

Malignant Peritoneal Effusion; Malignant Ascites · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active

40 / 69 pages

← PreviousNext →